Primary nonadherence, associated clinical outcomes, and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease-modifying antirheumatic drugs

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 3, 2016, Pages 209-218

  Harnett, James ^a   Wiederkehr, Daniel ^a   Gerber, Robert ^b   Gruben, David ^a   Bourret, Jeffrey ^a   Koenig, Andrew ^a  

^a PFIZER INC   (United States)

^b Outcomes and Evidence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; PRESCRIPTION DRUG;

ADULT; AGE; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTPATIENT; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; ELECTRONIC HEALTH RECORD; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; INJECTION; PROCEDURES; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DELIVERY OF HEALTH CARE; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH RESOURCES; HUMANS; INJECTIONS; MALE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85013979183     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/JMCP.2016.22.3.209     Document Type: Article

References (31)

1. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679-707
2. Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2012; (51 Suppl 5):v12-21
3. Van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2011;63(1):65-78
4. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39
5. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509
6. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(9):1367-78
7. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901-13
8. World Health Organization. Adherence to long-term therapies: evidence for action. 2003. Available at: http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf. Accessed November 30, 2015
9. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-90
10. Benjamin RM. Medication adherence: helping patients take their medicines as directed. Public Health Rep. 2012;127(1):2-3
11. IMS Institute for Healthcare Informatics. Avoidable costs in U.S. healthcare. The $200 billion opportunity from using medicines more responsibly. 2013 Available at: https://www.imshealth.com/en/thought-leadership/webinar-library/avoidable-costs-in-us-healthcare-200-billion-opportunity. Accessed November 30, 2015
12. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr., Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(10 Suppl 2):S66-76
13. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29(4):260-75
14. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633
15. Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication nonadherence after discharge from a general internal medicine service. PLoS One. 2013;8(5):e61735
16. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009;25(6):1365-77
17. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13(6):805-12
18. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(6 Suppl):S136-43
19. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient outof-pocket payments matter? Arthritis Rheum. 2008;59(10):1519-26
20. U.S. Department of Health & Human Services. Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. 2012. Available at: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/De-identification/guidance.html. Accessed November 30, 2015
21. Public welfare. Other requirements relating to uses and disclosures of protected health information. 45 CFR 164.514(b). April 23, 2015. Available at: http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=e0170bc87b10624 763295b7800ce770e&ty=HTML&h=L&=true&r=PART&n=pt45.1.164# se45.1.164_1514. Accessed November 30, 2015
22. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008;10(4):R95
23. Raebel MA, Carroll NM, Ellis JL, Schroeder EB, Bayliss EA. Importance of including early nonadherence in estimations of medication adherence. Ann Pharmacother. 2011;45(9):1053-60
24. Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011;124(11):1081.e9-22
25. Hopson S, Saverno KR, Liu LZ, AL-Sabbagh A, Orazem J, Pasquale MK. Impact of out-of-pocket costs on initial and subsequent prescription fills among new initiators of biologic therapies indicated for rheumatoid arthritis. Poster presented at: Academy of Managed Care Pharmacy 2014 Nexus; October 7-10, 2014; Boston, MA. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18543
26. Louder A, Singh A, Cappelleri J, Aten A, Koenig A, Pasquale M. Understanding patient preferences associated with the use of therapies for rheumatoid arthritis: results of a conjoint analysis. Arthritis & Rheumatism. 2014;66(11):S1043
27. Bennison C, Chansler M, Hibbard J, Turanin J. Adoption, adherence and preferences regarding injectable drug delivery by patients with rheumatoid arthritis: results of a research study. Poster presented at: AAPS National Biotechnology Conference, May 20-22; 2013; San Diego, CA. Available at: http://www.zogenix.com/content/technology/documents/AAPSPosterAdoptionofSelfInjectRxBennisonMay2013.pdf
28. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375-84
29. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007;21(5):929-42
30. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs. 1995;(50 Suppl):11-14
31. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640-47